Identification of a varicella-zoster virus replication inhibitor that blocks capsid assembly by interacting with the floor domain of the major capsid protein

Journal of Virology

Volumn 86, Issue 22, 2012, Pages 12198-12207

  Inoue, Naoki ^a   Matsushita, Misato ^a,b   Fukui, Yoshiko ^a   Yamada, Souichi ^a   Tsuda, Mihoko ^a   Higashi, Chizuka ^a,b   Kaneko, Keiko ^a   Hasegawa, Hideki ^a   Yamaguchi, Toyofumi ^b  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b TEIKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CAPSID PROTEIN; UNCLASSIFIED DRUG; VARICELLA ZOSTER VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; FIBROBLAST; GENE OVEREXPRESSION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; VARICELLA ZOSTER VIRUS; VCP GENE; VIRUS GENE; VIRUS REPLICATION;

ACYCLOVIR; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CAPSID; CAPSID PROTEINS; CELL LINE; CELL LINE, TUMOR; DNA, VIRAL; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; GENES, REPORTER; HEK293 CELLS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 3, HUMAN; HUMANS; MICROSCOPY, ELECTRON; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; VIRUS REPLICATION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 3; MIRIDAE;

EID: 84869137951     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01280-12     Document Type: Article

References (61)

1. Andrei G, et al. 2005. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob. Agents Chemother. 49:1081-1086.
2. Arvin AM. 2002. Antiviral therapy for varicella and herpes zoster. Semin. Pediatr. Infect. Dis. 13:12-21.
3. Baker ML, et al. 2003. Architecture of the herpes simplex virus major capsid protein derived from structural bioinformatics. J. Mol. Biol. 331: 447-456.
4. Bowman BR, Baker ML, Rixon FJ, Chiu W, Quiocho FA. 2003. Structure of the herpesvirus major capsid protein. EMBO J. 22:757-765.
5. Brunell PA, Casey HL. 1964. Crude tissue culture antigen for determination of varicella-zoster complement fixing antibody. Public Health Rep.79:839-842.
6. Chaudhuri V, Sommer M, Rajamani J, Zerboni L, Arvin AM. 2008. Functions of varicella-zoster virus ORF23 capsid protein in viral replication and the pathogenesis of skin infection. J. Virol. 82:10231-10246.
7. Chono K, et al. 2010. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J. Antimicrob. Chemother. 65:1733-1741.
8. Cohrs RJ, Gilden DH. 2007. Prevalence and abundance of latently transcribed varicella-zoster virus genes in human ganglia. J. Virol. 81:2950-2956.
9. Dal Pozzo F, et al. 2008. Fluorescence-based antiviral assay for the evaluation of compounds against vaccinia virus, varicella zoster virus and human cytomegalovirus. J. Virol. Methods 151:66-73.
10. Desai P, Person S. 1999. Second site mutations in the N-terminus of the major capsid protein (VP5) overcome a block at the maturation cleavage site of the capsid scaffold proteins of herpes simplex virus type 1. Virology 261:357-366.
11. Flynn DL, Abood NA, Holwerda BC. 1997. Recent advances in antiviral research: identification of inhibitors of the herpesvirus proteases. Curr. Opin. Chem. Biol. 1:190-196.
12. Fukui Y, et al. 2008. Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay. Antimicrob. Agents Chemother. 52:2420-2427.
13. Gao M, et al. 1994. The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth. J. Virol. 68:3702-3712.
14. Gates IV, et al. 2009. Quantitative measurement of varicella-zoster virus infection by semiautomated flow cytometry. Appl. Environ. Microbiol.75:2027-2036.
15. Gilbert C, Bestman-Smith J, Boivin G. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. 5:88-114.
16. Grose C, Brunel PA. 1978. Varicella-zoster virus: isolation and propagation in human melanoma cells at 36 and 32 degrees C. Infect. Immun.19:199-203.
17. Hartline CB, et al. 2005. Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity. Antiviral Res.65:97-105.
18. Heymann JB, et al. 2003. Dynamics of herpes simplex virus capsid maturation visualized by time-lapse cryo-electron microscopy. Nat. Struct. Biol. 10:334-341.
19. Homa FL, Brown JC. 1997. Capsid assembly and DNA packaging in herpes simplex virus. Rev. Med. Virol. 7:107-122.
20. Huang E, Perkins EM, Desai P. 2007. Structural features of the scaffold interaction domain at theNterminus of the major capsid protein (VP5) of herpes simplex virus type 1. J. Virol. 81:9396-9407.
21. Inoue N, Dambaugh TR, Rapp JC, Pellett PE. 1994. Alphaherpesvirus origin-binding protein homolog encoded by human herpesvirus 6B, a betaherpesvirus, binds to nucleotide sequences that are similar to ori regions of alphaherpesviruses. J. Virol. 68:4126-4136.
22. Inoue N, Winter J, Lal RB, Offermann MK, Koyano S. 2003. Characterization of entry mechanisms of human herpesvirus 8 by using an Rtadependent reporter cell line. J. Virol. 77:8147-8152.
23. Koshizuka T, Ota M, Yamanishi K, Mori Y. 2010. Characterization of varicella-zoster virus-encoded ORF0 gene- comparison of parental and vaccine strains. Virology 405:280-288.
24. Koyano S, Mar EC, Stamey FR, Inoue N. 2003. Glycoproteins M and N of human herpesvirus 8 form a complex and inhibit cell fusion. J. Gen. Virol. 84:1485-1491.
25. Ku CC, Padilla JA, Grose C, Butcher EC, Arvin AM. 2002. Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J. Virol. 76:11425-11433.
26. Levin MJ, et al. 2003. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J. Infect. Dis. 188:954-959.
27. Migliore M. 2010. FV-100: the most potent and selective anti-varicella zoster virus agent reported to date. Antivir. Chem. Chemother. 20:107-115.
28. Moffat JF, Stein MD, Kaneshima H, Arvin AM. 1995. Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J. Virol. 69:5236-5242.
29. Newcomb WW, Brown JC. 2002. Inhibition of herpes simplex virus replication by WAY-150138: assembly of capsids depleted of the portal and terminase proteins involved in DNA encapsidation. J. Virol. 76: 10084-10088.
30. Ogawa H, et al. 2007. Etiology of severe sensorineural hearing loss in children: independent impact of congenital cytomegalovirus infection and GJB2 mutations. J. Infect. Dis. 195:782-788.
31. Okamoto S, et al. 2004. Rapid detection of varicella-zoster virus infection by a loop-mediated isothermal amplification method. J. Med. Virol. 74: 677-682.
32. Preston VG, et al. 1997. Efficient herpes simplex virus type 1 (HSV-1) capsid formation directed by the varicella-zoster virus scaffolding protein requires the carboxy-terminal sequences from the HSV-1 homologue. J. Gen. Virol. 78:1633-1646.
33. Quinlivan ML, et al. 2011. Persistence of varicella-zoster virus viraemia in patients with herpes zoster. J. Clin. Virol. 50:130-135.
34. Reichelt M, Brady J, Arvin AM. 2009. The replication cycle of varicellazoster virus: analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at the single-cell level. J. Virol. 83:3904-3918.
35. Rowe J, Greenblatt RJ, Liu D, Moffat JF. 2010. Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice. Antiviral Res. 86:276-285.
36. Sahli R, Andrei G, Estrade C, Snoeck R, Meylan PR. 2000. A rapid phenotypic assay for detection of acyclovir-resistant varicella-zoster virus with mutations in the thymidine kinase open reading frame. Antimicrob. Agents Chemother. 44:873-878.
37. Salmon B, Cunningham C, Davison AJ, Harris WJ, Baines JD. 1998. The herpes simplex virus type 1 U(L)17 gene encodes virion tegument proteins that are required for cleavage and packaging of viral DNA. J. Virol. 72:3779-3788.
38. Sauerbrei A, Taut J, Zell R, Wutzler P. 2011. Resistance testing of clinical varicella-zoster virus strains. Antiviral Res. 90:242-247.
39. Schang LM. 2002. Cyclin-dependent kinases as cellular targets for antiviral drugs. J. Antimicrob. Chemother. 50:779-792.
40. Schnute ME, et al. 2005. 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. J. Med. Chem. 48:5794-5804.
41. Scholtes L, Baines JD. 2009. Effects of major capsid proteins, capsid assembly, and DNA cleavage/packaging on the pUL17/pUL25 complex of herpes simplex virus 1. J. Virol. 83:12725-12737.
42. Shahian T, et al. 2009. Inhibition of a viral enzyme by a small-molecule dimer disruptor. Nat. Chem. Biol. 5:640-646.
43. Shigeta S, et al. 1983. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J. Infect. Dis. 147:576-584.
44. Shiraki K, et al. 1992. Comparison of antiviral assay methods using cell-free and cell-associated varicella-zoster virus. Antiviral Res. 18:209-214.
45. Snoeck R, Andrei G, De Clercq E. 1999. Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs 57:187-206.
46. Soong W, Schultz JC, Patera AC, Sommer MH, Cohen JI. 2000. Infection of human T lymphocytes with varicella-zoster virus: an analysis with viral mutants and clinical isolates. J. Virol. 74:1864-1870.
47. Suzutani T, Ogasawara M, Shibaki T, Azuma M. 2000. Susceptibility of protein kinase (ORF47)-deficient varicella-zoster virus strains to antiherpesvirus nucleosides. Antiviral Res. 45:79-82.
48. Suzutani T, Saijo M, Nagamine M, Ogasawara M, Azuma M. 2000. Rapid phenotypic characterization method for herpes simplex virus and varicella-zoster virus thymidine kinases to screen for acyclovir-resistant viral infection. J. Clin. Microbiol. 38:1839-1844.
49. Takayama M, Takayama N, Inoue N, Kameoka Y. 1996. Application of long PCR method of identification of variations in nucleotide sequences among varicella-zoster virus isolates. J. Clin. Microbiol. 34:2869-2874.
50. Taylor SL, Kinchington PR, Brooks A, Moffat JF. 2004. Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus. J. Virol. 78:2853-2862.
51. Taylor SL, Moffat JF. 2005. Replication of varicella-zoster virus in human skin organ culture. J. Virol. 79:11501-11506.
52. Tipples GA, et al. 2002. New variant of varicella-zoster virus. Emerg. Infect. Dis. 8:1504-1505.
53. Trus BL, Gibson W, Cheng N, Steven AC. 1999. Capsid structure of simian cytomegalovirus from cryoelectron microscopy: evidence for tegument attachment sites. J. Virol. 73:2181-2192.
54. Trus BL, et al. 2001. Capsid structure of Kaposi's sarcoma-associated herpesvirus, a gammaherpesvirus, compared to those of an alphaherpesvirus, herpes simplex virus type 1, and a betaherpesvirus, cytomegalovirus. J. Virol. 75:2879-2890.
55. Visalli RJ, et al. 2003. Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. J. Virol. 77:2349-2358.
56. Walters JN, Sexton GL, McCaffery JM, Desai P. 2003. Mutation of single hydrophobic residue I27, L35, F39, L58, L65, L67, or L71 in theNterminus of VP5 abolishes interaction with the scaffold protein and prevents closure of herpes simplex virus type 1 capsid shells. J. Virol. 77:4043-4059.
57. Wang GQ, et al. 2006. Generation of a reporter cell line for detection of infectious varicella-zoster virus and its application to antiviral studies. Antimicrob. Agents Chemother. 50:3142-3145.
58. Warner SC, Desai P, Person S. 2000. Second-site mutations encoding residues 34 and 78 of the major capsid protein (VP5) of herpes simplex virus type 1 are important for overcoming a blocked maturation cleavage site of the capsid scaffold proteins. Virology 278:217-226.
59. Waxman L, Darke PL. 2000. The herpesvirus proteases as targets for antiviral chemotherapy. Antivir. Chem. Chemother. 11:1-22.
60. Williams-Aziz SL, et al. 2005. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother. 49:3724-3733.
61. Zhou ZH, et al. 2000. Seeing the herpesvirus capsid at 8.5 A. Science 288:877-880.